Diana Bilton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3311981/publications.pdf

Version: 2024-02-01

84 papers	5,219 citations	147786 31 h-index	91872 69 g-index
89 all docs	89 docs citations	89 times ranked	4920 citing authors

#	Article	IF	Citations
1	British Thoracic Society guideline for non-CFbronchiectasis. Thorax, 2010, 65, i1-i58.	5.6	838
2	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
3	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax, 2016, 71, i1-i22.	5.6	348
4	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax, 2016, 71, 88-90.	5.6	274
5	Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 975-982.	5.6	242
6	Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study Â Commentary: Management in paediatric and adult cystic fibrosis centres improves clinical outcome. BMJ: British Medical Journal, 1998, 316, 1771-1775.	2.3	209
7	Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. Journal of Cystic Fibrosis, 2020, 19, 68-79.	0.7	185
8	Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy, 2005, 55, 921-927.	3.0	168
9	Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. Journal of Cystic Fibrosis, 2011, 10, S79-S81.	0.7	165
10	Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. Journal of Cystic Fibrosis, 2018, 17, 218-227.	0.7	165
11	Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis. Chest, 2006, 130, 1503-1510.	0.8	145
12	Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax, 2014, 69, 1073-1079.	5.6	141
13	Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. European Respiratory Journal, 2011, 38, 1071-1080.	6.7	139
14	Lung Polymers in Z Î±₁-Antitrypsin Deficiency-related Emphysema. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 670-674.	2.9	132
15	Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. Journal of Cystic Fibrosis, 2013, 12, 130-140.	0.7	122
16	Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ: British Medical Journal, 2011, 342, d1008-d1008.	2.3	111
17	Phase 3 Randomized Study of the Efficacy and Safety of Inhaled Dry Powder Mannitol for the Symptomatic Treatment of Non-Cystic Fibrosis Bronchiectasis. Chest, 2013, 144, 215-225.	0.8	99
18	Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung. Antimicrobial Agents and Chemotherapy, 2016, 60, 744-751.	3.2	90

#	Article	IF	Citations
19	Structural explanation for the deficiency of S Î±1-antitrypsin. Nature Structural Biology, 1996, 3, 910-911.	9.7	87
20	Pseudomonas aeruginosaadaptation and diversification in the non-cystic fibrosis bronchiectasis lung. European Respiratory Journal, 2017, 49, 1602108.	6.7	75
21	Update on non-cystic fibrosis bronchiectasis. Current Opinion in Pulmonary Medicine, 2008, 14, 595-599.	2.6	67
22	Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 367-376.	0.7	63
23	BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. Journal of Cystic Fibrosis, 2014, 13, 156-163.	0.7	61
24	Data Resource Profile: The UK Cystic Fibrosis Registry. International Journal of Epidemiology, 2018, 47, 9-10e.	1.9	60
25	Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions. Respiratory Medicine, 2014, 108, 1397-1408.	2.9	58
26	HbA1c as a screening tool for cystic fibrosis related diabetes. Journal of Cystic Fibrosis, 2016, 15, 251-257.	0.7	57
27	The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. PLoS ONE, 2019, 14, e0212779.	2.5	54
28	Children and young adults with CF in the USA have better lung function compared with the UK. Thorax, 2015, 70, 229-236.	5.6	51
29	Placebo-Controlled Trials of Antioxidant Therapy Including S-Adenosylmethionine in Patients with Recurrent Nongallstone Pancreatitis. Drug Investigation, 1994, 8, 10-20.	0.6	39
30	Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. Clinical and Translational Science, 2017, 10, 28-34.	3.1	39
31	Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 284-291.	0.7	34
32	The reproducibility and responsiveness of the lung clearance index in bronchiectasis. European Respiratory Journal, 2015, 46, 1645-1653.	6.7	33
33	Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations. Journal of Cystic Fibrosis, 2017, 16, 36-40.	0.7	30
34	Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 151.	2.0	27
35	Global Lung Function Initiative equations improve interpretation of FEV₁ decline among patients with cystic fibrosis. European Respiratory Journal, 2015, 46, 262-264.	6.7	26
36	Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from the UK CF registry. Journal of Cystic Fibrosis, 2019, 18, 665-670.	0.7	26

#	Article	IF	Citations
37	Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. Journal of Cystic Fibrosis, 2015, 14, 632-638.	0.7	21
38	Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. Respiratory Medicine, 2015, 109, 357-363.	2.9	21
39	Heterogeneity of treatment response in bronchiectasis clinical trials. European Respiratory Journal, 2022, 59, 2100777.	6.7	21
40	Optimising inhaled mannitol for cystic fibrosis in an adult population. Breathe, 2015, 11, 39-48.	1.3	20
41	The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice. Medical Mycology, 2019, 57, 155-160.	0.7	20
42	Nurse specialist care for bronchiectasis. The Cochrane Library, 2003, , .	2.8	15
43	Investigating the effects of long-term dornase alfa use on lung function using registry data. Journal of Cystic Fibrosis, 2019, 18, 110-117.	0.7	15
44	The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK. Scientific Reports, 2020, 10, 10660.	3.3	14
45	Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. Journal of Cystic Fibrosis, 2022, 21, 302-308.	0.7	14
46	The expanding armamentarium of drugs to aid sputum clearance. Current Opinion in Pulmonary Medicine, 2014, 20, 601-606.	2.6	12
47	Results from an online survey of adults with cystic fibrosis: Accessing and using life expectancy information. PLoS ONE, 2019, 14, e0213639.	2.5	12
48	The isolation and characterization of non-typeable Haemophilus influenzae from the sputum of adult cystic fibrosis patients. European Respiratory Journal, 1995, 8, 948-53.	6.7	12
49	Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. Journal of Cystic Fibrosis, 2021, 20, 1010-1017.	0.7	11
50	Randomised cross-over trial evaluating the short-term effects of non-invasive ventilation as an adjunct to airway clearance techniques in adults with cystic fibrosis. BMJ Open Respiratory Research, 2019, 6, e000399.	3.0	9
51	Laboratory Diagnosis and Characterization of Fungal Disease in Patients with Cystic Fibrosis (CF): A Survey of Current UK Practice in a Cohort of Clinical Microbiology Laboratories. Mycopathologia, 2018, 183, 723-729.	3.1	8
52	Investigating outcome measures for assessing airway clearance techniques in adults with cystic fibrosis: protocol of a single-centre randomised controlled crossover trial. BMJ Open Respiratory Research, 2020, 7, e000694.	3.0	8
53	Adherence to Ivacaftor is suboptimal. Journal of Cystic Fibrosis, 2015, 14, 547-548.	0.7	6
54	Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis. European Respiratory Journal, 2015, 46, 862-865.	6.7	6

#	Article	IF	Citations
55	Long-term safety study of colistimethate sodium (ColobreatheÂ®): Findings from the UK Cystic Fibrosis Registry. Journal of Cystic Fibrosis, 2021, 20, 324-329.	0.7	6
56	Knowledge of pancreatic enzyme supplementation in adult cystic fibrosis (CF) patients. Journal of Human Nutrition and Dietetics, 2000, 13, 353-361.	2.5	5
57	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 695-701.	0.7	4
58	The impact of National Cystic Fibrosis Registries: A review series. Journal of Cystic Fibrosis, 2018, 17, 287-288.	0.7	4
59	S48 Mucoidy and the microbiome: community composition in relation to the presence of culturable, mucoid Pseudomonas aeruginosa. Thorax, 2011, 66, A24-A24.	5.6	3
60	Personalised medicine in cystic fibrosis must be made affordable. Paediatric Respiratory Reviews, 2014, 15, 6-7.	1.8	3
61	A new chapter in therapy for cystic fibrosis. Lancet Respiratory Medicine,the, 2015, 3, e20.	10.7	2
62	Response to Letter to the Editor: HbA1c as a screening tool for cystic fibrosis related diabetes. Journal of Cystic Fibrosis, 2016, 15, 265-266.	0.7	2
63	Letter to the editor. American Journal of Surgery, 1990, 160, 323-324.	1.8	1
64	P236 Cystic Fibrosis deaths in USA and UK: comparisons of registry and routine data. Thorax, 2011, 66, A163-A164.	5.6	1
65	S103â€…Anti-Pseudomonal Bacteriophage Cocktail Reduces Inflammatory Responses in the Murine Lung. Thorax, 2012, 67, A50.3-A51.	5.6	1
66	Azithromycin in bronchiectasis: evidence in children?. Lancet Respiratory Medicine,the, 2013, 1, 587-589.	10.7	1
67	S55â€…Towards the Clinical Application of Anti-pseudomonal Bacteriophage: Activity is Retained Following Nebulisation with a Range of Commercially Available Nebuliser Systems. Thorax, 2015, 70, A34.1-A34.	5.6	1
68	T4â€…Diabetes and pseudomonas, a terrible combination? examining the uk cystic fibrosis registry for a sex difference in outcomes (2008â€“2013). , 2017, , .		1
69	Heterogeneity of treatment response in bronchiectasis clinical trials. , 2020, , .		1
70	P227 Disparities in care of adult CF patients in the UK. Thorax, 2010, 65, A172-A173.	5.6	0
71	P103 Oral contraceptive use does not affect CF disease severity. Thorax, 2010, 65, A121-A121.	5.6	0
72	S122â€…Is There a Gender Difference in the UK CF Population?. Thorax, 2012, 67, A59.1-A59.	5.6	0

#	Article	IF	Citations
73	S123â€...The Role of Nasal Potential Difference Testing in Difficult Cases of Possible Cystic Fibrosis. Thorax, 2012, 67, A59.2-A59.	5.6	0
74	P175â€...The Short Term Variability of Sputum Microbiology in Non-CF Bronchiectasis. Thorax, 2012, 67, A139.1-A139.	5.6	0
75	P100â€...Successful eradication of respiratory tract MRSA in cystic fibrosis: a retrospective study. Thorax, 2013, 68, A120.1-A120.	5.6	0
76	S66 The Gli Spirometry Reference Equations Influence The Apparent Rate Of Decline In Fev1 Among Children And Adolescents With Cystic Fibrosis. Thorax, 2014, 69, A37-A37.	5.6	0
77	P200 Preliminary Evaluation Of The Fungal Airway Microbiome In Adult Cystic Fibrosis By Next-generation Sequencing, Culture And Staining Techniques. Thorax, 2014, 69, A164-A164.	5.6	0
78	P220â€...Using funnel plots to make meaningful centre comparisons. Thorax, 2015, 70, A187.2-A188.	5.6	0
79	USE OF APREPITANT AS AN ANTIEMETIC IN CYSTIC FIBROSIS PATIENTS. BMJ Supportive and Palliative Care, 2015, 5, 118.2-119.	1.6	0
80	S127â€...Are girls always thinner than boys? using uk cystic fibrosis (cf) registry data (2008â€“2013) to examine weight changes between the sexes from childhood and beyond. , 2017, , .		0
81	S91â€...Early growth trajectories in cystic fibrosis. , 2017, , .		0
82	The role of inhaled antibiotics in bronchial infection. , 2013, , 120-126.		0
83	Antibiotic treatment of cystic fibrosis lung disease. , 2014, , 188-202.		0
84	P243â€...Outcome measures for airway clearance in adults with cystic fibrosis (CF): a randomised controlled crossover trial. , 2019, , .		0